Hansa Medical ^Company

Hansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammatory diseases. The company runs three primary projects: IdeS, alpha-11 and HMD-301(HBP). Two of the products are developed in strategic partnership. IdeS is an innovative treatment within transplantation and autoimmune diseases. Alpha-11 is a novel and specific rheumatoid arthritis drug target. HMD-301 is a diagnostic method quantifying serum levels of the biomarker HBP, Heparin Binding Protein, for diagnosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED.